股票
板块
用户
资讯
首页
天眼
自选
发现
开户
首页
天眼
自选
发现
我的

成都先导与结构基因组学联盟(SGC)达成基于DEL技术的新药研发合作

 【中国成都,2023年9月28日】今天,上海证券交易所科创板上市公司成都先导药物开发股份有限公司(股票代码:688222.SH,以下简称“成都先导”)宣布与结构基因组学联盟(Structural Genomics Consortium,以下简称“SGC”)建立合作伙伴关系。成都先导将利用其DNA编码化合物库(DEL)技术平台的产品OpenDEL?针对SGC关注的新靶点进行筛选。该项目的筛选数据集将以适合ML(机器学习)的格式发布在公开平台,以便世界各地的药物发现和ML专家访问、进行数据建模,并应用于预测新的活性分子。作为全球开放科学运动“Target 2035”计划的一部分,预测出的新活性分子将在SGC进行实验测试。成都先导是DEL技术开发及其在小分子新药研发领域应用的全球领导者,其DEL技术平台可设计、合成和筛选包含超过1.2万亿DNA编码化合物的实体分子库。公司拥有的DEL产品以及高效筛选能力已为全球多个机构和组织提供新药发现服务及项目。OpenDEL?是一款自助式DEL筛选服务产品,总化合物数量达30亿,用户可在不透露靶点信息的情况下进行DEL筛选。在产品手册及操作说明指导下,用户可自主完成蛋白靶点的亲和力筛选实验。同时,成都先导亦可提供上下游技术服务。成都先导董事长兼首席执行官李进博士表示:“我们期待与SGC的研究团队开展合作,针对缺少研究的蛋白靶点开发新颖的化合物起点,并在公共平台上开放相关数据集用于AI/ML(人工智能/机器学习)研究。成都先导拥有世界领先的DEL技术平台,是发现新药‘种子’的高效‘引擎’。作为公司的四个核心技术平台之一,DEL技术平台已经为众多客户和合作伙伴的创新药物发现项目提供了新颖的起点化合物。我们也十分期待为SGC关注的靶点筛选出有价值的化合物起点。”SGC首席执行官Aled Edwards表示:“我相信,此次双方的合作有望带来变革性的影响。我们期待为ML(机器学习)领域提供高质量、经过精心整理的数据,利用ML找到所有人类蛋白靶点的药物研究起点。”关于成都先导成都先导药物开发股份有限公司(上海证券交易所股票代码:688222.SH,股票名称:成都先导)致力于打造全球一流的创新型生物医药企业,总部位于中国成都,在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化,着力打造了国际领先的DNA编码化合物库技术(包括DEL库的设计、合成和筛选及拓展应用)平台,并拓展了基于分子片段和三维结构信息的药物设计技术(FBDD/SBDD)、寡聚核酸新药研发相关技术(STO)和靶向蛋白降解相关技术(TPD)的核心技术平台。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式,成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前,公司有多个内部新药项目处于临床及临床前不同阶段。关于结构基因组学盟(SGC)结构基因组学联盟(Structural Genomics Consortium,SGC)是一个全球性的公私合作组织,旨在通过促进学术界和工业界之间的科学家合作,并向科学界公开所有研究成果,从而加速推动药物发现。目前,SGC的研究基地位于法兰克福歌德大学、卡罗林斯卡学院、麦吉尔大学、伦敦大学学院、北卡罗来纳大学教堂山分校、多伦多大学。如需了解更多信息,请联系 Sofia Melliou:communications@thesgc.orgSGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug DiscoveryCHENGDU, China, September 28, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL?, to screen under-represented targets chosen by SGC.  The screening datasets, curated in a ML-ready format, will be posted to a publicly accessible portal to facilitate drug discovery and ML experts from around the world to model the data and make predictions about new active molecules that would be experimentally tested at SGC as part of the Target 2035 initiative. HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology, and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.OpenDEL? is a self-service DEL kit with over 3 billion compounds, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL? to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support.“We look forward to working with the research teams at SGC to generate novel starting points for under-studied proteins and to place ML-ready representations of the data into the public domain on an open access basis. As one of HitGen’s four core technology platforms, our world-leading DEL platform is an efficient ‘engine’ to advance drug discovery and has enabled hit identification and lead generation for many innovative discovery programs by our customers and partners. We look forward to delivering useful starting points for targets chosen by SGC,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc.“I am confident that this partnership has the potential to be transformative,” said Aled Edwards, Chief Executive of the SGC, “We look forward to providing the ML community with high-quality, well-curated data so they can contribute to our global effort to find drug starting points for all human proteins.”About HitGen Inc.HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.For media inquiries: media@hitgen.comFor investor inquiries: investors@hitgen.com For business development: bd@hitgen.comAbout the Structural Genomics ConsortiumThe Structural Genomics Consortium is a global public-private partnership that seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and making all research outputs openly available to the scientific community. The current SGC research sites are located at Goethe University in Frankfurt, Karolinska Institute, McGill University, University College, London, the University of North Carolina, Chapel Hill, and the University of Toronto.For more information, contact Sofia Melliou: communications@thesgc.org获取更多信息,请致电+86-28-85197385或访问www.hitgen.com。媒体查询:media@hitgen.com投资者咨询:investors@hitgen.com商务开发:bd@hitgen.com
原文链接
多空观点 观点仅供交流,不构成投资建议
点赞
踩一踩
收藏
分享

评论 (0)

0/200
声明:社区内容仅代表用户个人观点,不构成任何投资建议。投资有风险,入市需谨慎。